Float Short %

13.91

Margin Of Safety %

Put/Call OI Ratio

0.39

EPS Next Q Diff

0.09

EPS Last/This Y

-0.48

EPS This/Next Y

-0.18

Price

87.43

Target Price

116.71

Analyst Recom

1.25

Performance Q

35.9

Upside

-153.5%

Beta

2.22

Ticker: KYMR

20 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-01-23	KYMR	69.93	0.77	0.40	1478
2026-01-26	KYMR	71.13	0.77	0.25	1484
2026-01-27	KYMR	72.14	0.77	2.00	1488
2026-01-28	KYMR	71.19	0.77	2.00	1488
2026-01-29	KYMR	73.87	0.77	0.00	1489
2026-01-30	KYMR	72.75	0.48	2.00	1997
2026-02-02	KYMR	75.65	0.48	0.28	1998
2026-02-03	KYMR	77.32	0.47	0.20	2080
2026-02-04	KYMR	77.71	0.46	10.00	2203
2026-02-05	KYMR	75.95	0.47	0.00	2224
2026-02-06	KYMR	79.58	0.45	0.00	2289
2026-02-09	KYMR	79.14	0.42	0.07	2399
2026-02-10	KYMR	79.55	0.42	0.00	2413
2026-02-11	KYMR	82.36	0.41	0.02	2452
2026-02-12	KYMR	84.17	0.37	0.21	2754
2026-02-13	KYMR	82.38	0.36	2.63	2977
2026-02-17	KYMR	84.84	0.37	2.26	2992
2026-02-18	KYMR	85.2	0.39	5.64	3022
2026-02-19	KYMR	86.46	0.39	0.00	3026
2026-02-20	KYMR	87.43	0.39	0.74	3025
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

20 items 1 of 1

20 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-01-23	KYMR	69.91	11.9	-8.3	-3.46
2026-01-26	KYMR	71.07	11.9	-27.3	-3.46
2026-01-27	KYMR	72.14	11.9	-26.9	-3.46
2026-01-28	KYMR	71.19	11.9	-17.1	-3.46
2026-01-29	KYMR	73.84	11.9	-34.4	-3.46
2026-01-30	KYMR	72.70	8.9	-16.3	-3.46
2026-02-02	KYMR	75.64	8.9	-35.5	-3.46
2026-02-03	KYMR	77.21	8.6	-28.8	-3.46
2026-02-04	KYMR	77.61	8.6	-23.3	-3.46
2026-02-05	KYMR	75.98	8.6	-14.1	-3.46
2026-02-06	KYMR	79.57	8.6	-38.4	-3.46
2026-02-09	KYMR	79.05	8.6	-19.7	-3.46
2026-02-10	KYMR	79.56	9.1	-24.0	-3.46
2026-02-11	KYMR	82.36	9.1	-33.8	-3.46
2026-02-12	KYMR	84.16	9.1	-29.1	-3.46
2026-02-13	KYMR	82.36	9.1	-15.0	-3.46
2026-02-17	KYMR	84.84	11.5	-31.7	-3.46
2026-02-18	KYMR	85.09	11.5	-22.7	-3.46
2026-02-19	KYMR	86.52	11.5	-	-3.46
2026-02-20	KYMR	87.43	11.5	-	-3.46
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

20 items 1 of 1

20 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-01-23	KYMR	12.54	6.32	11.87
2026-01-26	KYMR	12.54	6.16	11.87
2026-01-27	KYMR	12.54	6.16	11.87
2026-01-28	KYMR	12.54	6.16	12.94
2026-01-29	KYMR	12.54	6.16	12.94
2026-01-30	KYMR	12.54	6.16	12.94
2026-02-02	KYMR	12.54	6.13	12.94
2026-02-03	KYMR	12.54	6.13	12.94
2026-02-04	KYMR	12.54	6.13	12.94
2026-02-05	KYMR	12.54	6.13	12.94
2026-02-06	KYMR	12.54	6.13	12.94
2026-02-09	KYMR	12.54	6.31	12.94
2026-02-10	KYMR	12.54	6.31	12.94
2026-02-11	KYMR	12.54	6.31	13.99
2026-02-12	KYMR	12.54	6.31	13.90
2026-02-13	KYMR	13.08	6.31	13.90
2026-02-17	KYMR	13.08	8.22	13.91
2026-02-18	KYMR	13.02	8.22	13.91
2026-02-19	KYMR	13.02	8.22	13.91
2026-02-20	KYMR	13.02	8.22	13.91
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

20 items 1 of 1

Last Quarter Act. EPS

-0.94

Avg. EPS Est. Current Quarter

-0.78

Avg. EPS Est. Next Quarter

-0.85

Insider Transactions

13.02

Institutional Transactions

8.22

Beta

2.22

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

15.1

Max Drawdown 5-Year %

-83.5

Target Price

116.71

P/E

Forward P/E

PEG

P/S

157.79

P/B

6.63

P/Free Cash Flow

EPS

-3.6

Average EPS Est. Cur. Y

-3.46

EPS Next Y. (Est.)

-3.64

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-674.81

Relative Volume

1.06

Return on Equity vs Sector %

-60.2

Return on Equity vs Industry %

-42.7

EPS 1 7Days Diff

EPS 1 30Days Diff

0.01

EBIT Estimation

Kymera Therapeutics, Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 225

Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa and atopic dermatitis. The company also develops STAT6, a type 2 inflammation in allergic and atopic diseases; and TYK2 to treat autoimmune and inflammatory diseases. The company has a strategic alliance with Sanofi S.A. for the development of drug candidates targeting IRAK4 outside of the oncology and immuno-oncology fields. Kymera Therapeutics, Inc. was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

stock quote shares KYMR – Kymera Therapeutics, Inc. Stock Price stock today

news today KYMR – Kymera Therapeutics, Inc. stock forecast ,stock prediction 2023 2024 2025

marketwatch KYMR – Kymera Therapeutics, Inc. yahoo finance google finance

stock history KYMR – Kymera Therapeutics, Inc. invest stock market

stock prices KYMR premarket after hours

ticker KYMR fair value insiders trading

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Upside

Beta

Ticker: KYMR

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Last Quarter Act. EPS

Average EPS Est. Cur. Y